Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of recombinant von Willebrand factor with or without ADVATE for elective surgery in severe von Willebrand disease
NL-OMON42081Phase 3Withdrawn
- Sponsor
- Baxalta
- Start
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa and recombinant human coagulation factor VIII in von Willebrand disease (VWD), sponsored by Baxalta. Primary endpoint: Overall hemostatic efficacy. Planned start Dec 2014; status: withdrawn.
02
Drugs
vonicog alfarecombinant human coagulation factor VIII
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NL-OMON42081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42081.